Table 1.
Patient Characteristics by Dose Group.
| < 75 Gy | 75-79.9 Gy | ≥ 80 Gy | p-value | |
|---|---|---|---|---|
| Number of Patients | 50 | 60 | 116 | |
| T-category | ||||
| T1 | 8 (16) | 7 (12) | 31 (27) | 0.017 |
| T2 | 23 (46) | 33 (55) | 45 (39) | |
| T3/T4 | 18 (36) | 12 (20) | 26 (22) | |
| TX | 1 (2) | 8(13) | 14(12) | |
| Initial PSA (ng/mL) | ||||
| <10 | 15 (30) | 24 (40) | 56 (48) | 0.043 |
| 10-<20 | 16 (32) | 18 (30) | 40 (35) | |
| ≥20 | 19 (38) | 18 (30) | 20 (17) | |
| Gleason Score | ||||
| 8 | 34 (68) | 37 (62) | 99 (85) | 0.003 |
| 9 | 12 (24) | 20 (33) | 13 (11) | |
| 10 | 4 (8) | 3 (5) | 4 (3) | |
| Received ADT | 27 (54) | 39 (65) | 100 (86) | <0.001 |
| ADT Duration, months median |
12.0 | 22.2 | 28.0 | 0.002 |
| RT Technique | ||||
| Conventional | 8 (16) | 0 (0) | 0 (0) | <0.001 |
| 3D Conformal | 42 (84) | 58 (97) | 81 (70) | |
| IMRT | 0 (0) | 2 (3) | 35 (30) | |
| Age, years median (range) |
73 (55-89) | 68 (54-82) | 71 (41-86) | 0.141 |
| Follow-up, months median (range) |
66.2 (11.4-173.5) |
70.9(9.9-126.3) | 58.4 (4.9-105.9) |
0.002 |
Table values are number of patients (percent of dose group) unless otherwise noted. Abbreviations: Gray (Gy), palpation tumor category (T-category), prostate specific antigen (PSA), androgen deprivation therapy (ADT), radiation therapy (RT), intensity modulated RT (IMRT).